Literature DB >> 28718700

Use of single-dose oral gabapentin to attenuate fear responses in cage-trap confined community cats: a double-blind, placebo-controlled field trial.

Katherine E Pankratz1, Kelli K Ferris1, Emily H Griffith2, Barbara L Sherman1.   

Abstract

Objectives This double-blind, placebo-controlled study evaluated the safety and efficacy of single-dose oral gabapentin administered for the attenuation of fear responses in cage-trap confined community cats. Methods Community cats presented in cage traps for trap-neuter-return (TNR) were recruited and screened for inclusion. Each enrolled cat was randomly assigned and administered one of three equal-volume, single-dose treatments: placebo, low-dose gabapentin (50 mg) or high-dose gabapentin (100 mg). At baseline, 1, 2, 3 and 12 h post-administration, a single, blinded observer scored each cat for signs of fear and sedation using published paradigms, calculated the respiratory rate and documented any observable facial injuries. Results Fifty-three cats met the inclusion criteria and completed the study. Cat stress score (a measure of fear) was lower in cats that received gabapentin (50 or 100 mg) than in cats that received placebo (50 mg: P = 0.027; 100 mg: P = 0.029), with the greatest reduction at 2 h post-treatment ( P = 0.0007). Respiratory rates did not differ between treatment groups. There was no difference in sedation scores between the groups ( P = 0.86) at any time point ( P = 0.09). Cat facial injuries did not vary by treatment group or over time. No adverse effects were detected specific to gabapentin administration. At 1 h, hypersalivation was observed in four cats across all treatment groups. All cats recovered from surgery and anesthesia uneventfully. Conclusions and relevance This study supports the hypothesis that 50 mg or 100 mg gabapentin (9.2-47.6 mg/kg per cat) reduces fear responses in confined community cats without measurable sedation over 3 h post-administration vs placebo. Gabapentin treatment was well tolerated in this population of cats. Further studies are recommended to investigate the use of oral gabapentin earlier in the TNR process, such as immediately after trapping or prior to transport for the prevention of confinement-related injuries.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28718700     DOI: 10.1177/1098612X17719399

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  5 in total

1.  Serum concentrations of gabapentin in cats with chronic kidney disease.

Authors:  Jessica M Quimby; Sarah K Lorbach; Ashlie Saffire; Amanda Kennedy; Luke A Wittenburg; Turi K Aarnes; Karina J Creighton; Sarah E Jones; Rene E Paschall; Emily M King; Clara E Bruner; Jessica N Wallinger; Karen A van Haaften
Journal:  J Feline Med Surg       Date:  2022-02-23       Impact factor: 1.971

2.  Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses.

Authors:  Jenifer R Gold; Tamara L Grubb; Sherry Cox; Lais Malavasi; Nicholas L Villarino
Journal:  J Vet Intern Med       Date:  2022-02-12       Impact factor: 3.333

3.  Randomised clinical trial evaluating the effect of a single preappointment dose of gabapentin on signs of stress in hyperthyroid cats.

Authors:  Matthew Gurney; Lou Gower
Journal:  J Feline Med Surg       Date:  2022-04-28       Impact factor: 1.971

4.  ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats.

Authors:  Virginia Luis Fuentes; Jonathan Abbott; Valérie Chetboul; Etienne Côté; Philip R Fox; Jens Häggström; Mark D Kittleson; Karsten Schober; Joshua A Stern
Journal:  J Vet Intern Med       Date:  2020-04-03       Impact factor: 3.333

5.  Short Term Safety, Immunogenicity, and Reproductive Effects of Combined Vaccination With Anti-GnRH (Gonacon) and Rabies Vaccines in Female Feral Cats.

Authors:  Shiri Novak; Boris Yakobson; Shir Sorek; Liat Morgan; Smadar Tal; Ran Nivy; Roni King; Lauren Jaebker; Douglas C Eckery; Tal Raz
Journal:  Front Vet Sci       Date:  2021-05-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.